Safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population

M.V.W. Van Der Velden, R.S. Fritz, E.M. Pöllabauer, D. Portsmouth, M.K. Howard, T.R. Kreil, T. Dvorak, S. Fritsch, T.H. Vesikari, J. Díez Domingo, Peter Richmond, B. Lee, O. Kistner, H.J. Ehrlich, P.N. Barrett, G. Aichinger

    Research output: Contribution to journalArticlepeer-review

    27 Citations (Scopus)


    Background. Children are highly vulnerable to infection with novel influenza viruses. It is essential to develop candidate pandemic influenza vaccines that are safe and effective in the pediatric population.Methods. Infants and children aged 6-35 months and 3-8 years, respectively, were randomized to receive 2 immunizations with a 7.5-g or 3.75-g hemagglutinin (HA) dose of a nonadjuvanted whole-virus A/Vietnam(H5N1) vaccine; adolescents aged 9-17 years received a 7.5-g dose only. A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine approximately 1 year later. HA and neuraminidase antibody responses were assessed.Results. Vaccination was safe and well tolerated; adverse reactions were transient and predominantly mild. Two immunizations with the 7.5-g dose of A/Vietnam vaccine induced virus microneutralization (MN) titers of ≥1:20 against the A/Vietnam strain in 68.8%-85.4% of participants in the different age groups. After the booster, 93.1%-100% of participants achieved MN titers of ≥1:20 against the A/Vietnam and A/Indonesia strains. Neuraminidase-inhibiting antibodies were induced in ≥90% of participants after 2 immunizations with the 7.5 g A/Vietnam vaccine and in 100% of participants after the booster.Conclusions. A whole-virus influenza A(H5N1) vaccine is suitable for prepandemic or pandemic immunization in a pediatric population.Clinical Trials Registration. NCT01052402. © 2013 The Author.
    Original languageEnglish
    Pages (from-to)12-23
    JournalJournal of Infectious Diseases
    Issue number1
    Publication statusPublished - 2014


    Dive into the research topics of 'Safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population'. Together they form a unique fingerprint.

    Cite this